Pathologic variants in TP53 are known risk factors for the development of cancer. We report a 17-year-old male who presented with two primary sarcomas. Germline sequencing revealed a novel TP53 c.672 G>A mutation. Sequencing revealed wild-type TP53 in the parents, and there was no history of cancer in first-degree relatives. This de novo synonymous germline mutation results in a 5 ′ cryptic splice site that is bound by U1, resulting in a shift of the splice site by 5 base pairs. The frame shift results in a truncated protein at residue 246, which disrupts the DNAbinding domain of p53.
INTRODUCTION
TP53 is the most frequently mutated gene in human cancer. 1 Encoded by 13 exons, this gene has many genetic polymorphisms leading to more than 100 haplotypes and through alternative splicing 12 nonpathogenic protein isoforms. 2, 3 To date, none of the nonpathogenic isoforms have splicing alterations in the exons 6 and 7. Most TP53 mutations associated with cancer result from a missense substitution (73%) leading to an amino acid substitution in the DNA-binding domain.
Other changes include frameshift insertions and deletions (9%), nonsense mutations (8%), silent mutations (4%), and splice site mutations (2%; IARC TP53 database). 4 These mutations typically result in a full- The classic definition of Li-Fraumeni syndrome includes one proband with sarcoma less than 45 years of age, a first-degree relative with cancer prior to the age of 45, and a first-or second-degree Abbreviations: bm, bone marrow; bp, base pair relative with any cancer before 45 years of age or a sarcoma at any age. 5 Birch and Eeles modified the criteria, leading to the nomenclature of "Li-Fraumeni-like syndrome," which still requires two relatives with cancer. TP53 mutations (7-24%) are de novo mutations. 6, 7 Carriers with TP53 pathogenic variants have a 40% probability of cancer by 20 years and greater than 90% by 70 years. These mutations produce an 83-fold risk of developing multiple tumors. 8 We describe an adolescent who presented with two different sarcomas. Sequencing revealed a germline synonymous mutation in the DNA-binding domain of TP53, which produces a 5 ′ cryptic splice site that results in a frame shift in the amino acids translated resulting in a premature termination at amino acid 246, disrupting the DNA-binding domain of p53.
CASE REPORT
A 17-year-old fraternal twin male, the product of in vitro fertilization (IVF), presented with hematuria. He was initially diagnosed with pleomorphic sarcoma, most likely a leiomyosarcoma, of the pelvis ( and 1B). During the workup for metastasis, he was found to have a left humeral mass, which was biopsied and determined to be a telangiectatic osteosarcoma ( Fig. 1C and 1D ). His bone marrow (bm) at diagnosis had no evidence of disease. He completed five cycles of ifosfamide/doxorubicin and local radiation, followed by surgical resection, of the pelvic tumor. His disease progressed postoperatively, and he died 13 months from his initial diagnosis. There was no family history of cancer, other than a maternal uncle diagnosed with a glioblastoma multiforme in his seventh decade.
METHODS AND RESULTS
Following informed consent, the patient and his parents provided peripheral blood lymphocytes for TP53 DNA sequencing, performed by GeneDx. Sequencing of DNA from peripheral blood lymphocytes from the patient, but not his parents, revealed c.672 G>A germline variant preserving the glutamate at p. 224. However, this mutation is located at the last base pair (bp) of exon 6. An in silico algorithm (http://in-silico.net/tools/biology/sequence_conversion) predicts that this novel mutation produces a 5 ′ cryptic splice site at an alternative location.
Total RNA was then extracted from formaldehyde-fixed paraffinembedded bm and leiomyosarcoma. 9 RNA was then transcribed into cDNA using SuperScript VILO master mix containing random primers (Invitrogen, Carlsbad, CA). The RNA yield, as well as the quality, was low (0.02 and 0.01 g/ l). Short fragments of <150 bp were amplified and the best sets amplified 131 bp using nested polymerase chain reaction (PCR). Primers were designed to amplify the region spanning exons 6 and 7 junction (Fig. 2A) . Amplified fragments were resolved by MetaPhor agarose gel, which demonstrated doublets (Fig. 2B) .
The higher molecular weight band seen in the samples is consistent with intronic retention (arrow in Fig. 2B ). We believe the mutation is germline due to its presence in the bm where he had no evidence of disease. However, the expression of the mutant mRNA seems to be more stable in the bm, whereas the doublet in the tumor has less definition. The two amplified fragments were isolated from the gel and sequenced, using Sanger sequencing (GENEWIZ, South Plainfield, NJ). Sequencing of the 131 bp fragment proved challenging. To better delineate the mutation in such a small fragments, the fragments were inserted into the pcDNA3 plasmid (Invitrogen) resulting in sequencing of the entire fragment. Figure 2C shows the insertion of 5 bp from the intron in the mutated strand. Supplementary Figure S1 shows sequencing from the controls samples.
DISCUSSION
We performed a search and surveyed the online TP53 data in IARC TP53, NCBI dbSNP, and ExAc for mutations and their effects on the structure of p53 and its DNA-binding site. Other patients harbored synonymous mutations G>T and G>C at this site. His novel germline mutations (G>A), we predicted, would result in a splice variant based on the conserved sequences for splicing at the end of the exon, but has not been previously described in the literature. The U1 splicing complex binds to the 5 ′ intron-exon border based on conserved sequences.
A mutation in these conserved sequences can result in a shift of the spliceosome binding site and insertion of intronic sequence into the mRNA transcript. We have found no reports of our patient's mutation. Review of the literature found a reported family with a G>A at 
